Literature DB >> 23095052

Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report.

J A S Crippa1, J E C Hallak, J P Machado-de-Sousa, R H C Queiroz, M Bergamaschi, M H N Chagas, A W Zuardi.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Cannabis withdrawal in heavy users is commonly followed by increased anxiety, insomnia, loss of appetite, migraine, irritability, restlessness and other physical and psychological signs. Tolerance to cannabis and cannabis withdrawal symptoms are believed to be the result of the desensitization of CB1 receptors by THC. CASE
SUMMARY: This report describes the case of a 19-year-old woman with cannabis withdrawal syndrome treated with cannabidiol (CBD) for 10 days. Daily symptom assessments demonstrated the absence of significant withdrawal, anxiety and dissociative symptoms during the treatment. WHAT IS NEW AND
CONCLUSION: CBD can be effective for the treatment of cannabis withdrawal syndrome.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23095052     DOI: 10.1111/jcpt.12018

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  25 in total

Review 1.  The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products.

Authors:  Lisa K Brents; Paul L Prather
Journal:  Drug Metab Rev       Date:  2013-09-24       Impact factor: 4.518

2.  Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal.

Authors:  Francisco Navarrete; Auxiliadora Aracil-Fernández; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2018-05-03       Impact factor: 8.739

3.  Novel Pharmacologic Approaches to Treating Cannabis Use Disorder.

Authors:  Rebecca E Balter; Ziva D Cooper; Margaret Haney
Journal:  Curr Addict Rep       Date:  2014-06-01

4.  With pot now legal, therapies sought to blunt high of marijuana.

Authors:  Brian Owens
Journal:  Nat Med       Date:  2014-02       Impact factor: 53.440

Review 5.  Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.

Authors:  G M Mandolini; M Lazzaretti; A Pigoni; L Oldani; G Delvecchio; P Brambilla
Journal:  Epidemiol Psychiatr Sci       Date:  2018-05-23       Impact factor: 6.892

6.  Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.

Authors:  Tom P Freeman; Chandni Hindocha; Gianluca Baio; Natacha D C Shaban; Emily M Thomas; Danica Astbury; Abigail M Freeman; Rachel Lees; Sam Craft; Paul D Morrison; Michael A P Bloomfield; Dominic O'Ryan; Jane Kinghorn; Celia J A Morgan; Ali Mofeez; H Valerie Curran
Journal:  Lancet Psychiatry       Date:  2020-07-28       Impact factor: 27.083

Review 7.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 8.  Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?

Authors:  Natalie E Zlebnik; Joseph F Cheer
Journal:  Annu Rev Neurosci       Date:  2016-02-24       Impact factor: 12.449

9.  Cannabidiol Oil for Decreasing Addictive Use of Marijuana: A Case Report.

Authors:  Scott Shannon; Janet Opila-Lehman
Journal:  Integr Med (Encinitas)       Date:  2015-12

10. 

Authors:  Jairo Vinícius Pinto; Gayatri Saraf; Christian Frysch; Daniel Vigo; Kamyar Keramatian; Trisha Chakrabarty; Raymond W Lam; Márcia Kauer-Sant'Anna; Lakshmi N Yatham
Journal:  Can J Psychiatry       Date:  2019-12-13       Impact factor: 4.356

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.